COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study
Nicola Fazio
,
Lorenzo Gervaso
,
Thorvardur Halfdanarson
,
Mohamad Sonbol
,
Rachel Eiring
,
Sara Pusceddu
,
Natalie Prinzi
,
Benedetta Lombardi Stocchetti
,
Simona Grozinsky-Glasberg
,
David Gross
,
Thomas Walter
(1, 2, 3, 4)
,
Patrick Robelin
,
Catherine Lombard-Bohas
,
Samuele Frassoni
,
Vincenzo Bagnardi
,
Lorenzo Antonuzzo
,
Clotilde Sparano
,
Sara Massironi
,
Fabio Gelsomino
,
Alberto Bongiovanni
,
Nicoletta Ranallo
,
Salvatore Tafuto
,
Maura Rossi
,
Mauro Cives
,
Ibrahim Rasul Kakil
,
Hytam Hamid
,
Alessandra Chirco
,
Michela Squadroni
,
Anna La Salvia
,
Jorge Hernando
,
Johannes Hofland
,
Anna Koumarianou
,
Sabrina Boselli
,
Darina Tamayo
,
Cristina Mazzon
,
Manila Rubino
,
Francesca Spada
Nicola Fazio
- Fonction : Auteur
- PersonId : 1359879
- ORCID : 0000-0001-6869-0704
Lorenzo Gervaso
- Fonction : Auteur
- PersonId : 1359880
- ORCID : 0000-0003-3313-8527
Thorvardur Halfdanarson
- Fonction : Auteur
- PersonId : 1359881
- ORCID : 0000-0001-8460-1257
Mohamad Sonbol
- Fonction : Auteur
Rachel Eiring
- Fonction : Auteur
Sara Pusceddu
- Fonction : Auteur
Natalie Prinzi
- Fonction : Auteur
Benedetta Lombardi Stocchetti
- Fonction : Auteur
Simona Grozinsky-Glasberg
- Fonction : Auteur
- PersonId : 1359882
- ORCID : 0000-0002-1014-9154
David Gross
- Fonction : Auteur
Thomas Walter
- Fonction : Auteur
- PersonId : 766421
- IdHAL : thomas-walter01
- ORCID : 0000-0002-4199-4561
Patrick Robelin
- Fonction : Auteur
Catherine Lombard-Bohas
- Fonction : Auteur
Samuele Frassoni
- Fonction : Auteur
Vincenzo Bagnardi
- Fonction : Auteur
Lorenzo Antonuzzo
- Fonction : Auteur
Clotilde Sparano
- Fonction : Auteur
- PersonId : 1189534
- ORCID : 0000-0002-3766-4682
Sara Massironi
- Fonction : Auteur
- PersonId : 1359883
- ORCID : 0000-0003-3214-8192
Fabio Gelsomino
- Fonction : Auteur
Alberto Bongiovanni
- Fonction : Auteur
Nicoletta Ranallo
- Fonction : Auteur
Salvatore Tafuto
- Fonction : Auteur
Maura Rossi
- Fonction : Auteur
Mauro Cives
- Fonction : Auteur
Ibrahim Rasul Kakil
- Fonction : Auteur
Hytam Hamid
- Fonction : Auteur
Alessandra Chirco
- Fonction : Auteur
Michela Squadroni
- Fonction : Auteur
Anna La Salvia
- Fonction : Auteur
Jorge Hernando
- Fonction : Auteur
Johannes Hofland
- Fonction : Auteur
- PersonId : 1359884
- ORCID : 0000-0003-0679-6209
Anna Koumarianou
- Fonction : Auteur
Sabrina Boselli
- Fonction : Auteur
Darina Tamayo
- Fonction : Auteur
Cristina Mazzon
- Fonction : Auteur
Manila Rubino
- Fonction : Auteur
Francesca Spada
- Fonction : Auteur
Résumé
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
Format du dépôt | Notice |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study
|
Résumé |
en
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
|
Auteur(s) |
Nicola Fazio
, Lorenzo Gervaso
, Thorvardur Halfdanarson
, Mohamad Sonbol
, Rachel Eiring
, Sara Pusceddu
, Natalie Prinzi
, Benedetta Lombardi Stocchetti
, Simona Grozinsky-Glasberg
, David Gross
, Thomas Walter
1, 2, 3, 4
, Patrick Robelin
, Catherine Lombard-Bohas
, Samuele Frassoni
, Vincenzo Bagnardi
, Lorenzo Antonuzzo
, Clotilde Sparano
, Sara Massironi
, Fabio Gelsomino
, Alberto Bongiovanni
, Nicoletta Ranallo
, Salvatore Tafuto
, Maura Rossi
, Mauro Cives
, Ibrahim Rasul Kakil
, Hytam Hamid
, Alessandra Chirco
, Michela Squadroni
, Anna La Salvia
, Jorge Hernando
, Johannes Hofland
, Anna Koumarianou
, Sabrina Boselli
, Darina Tamayo
, Cristina Mazzon
, Manila Rubino
, Francesca Spada
1
HCL -
Hospices Civils de Lyon
( 300074 )
- 3 Quai des Célestins
69002 Lyon
- France
2
UNICANCER/CRCL -
Centre de Recherche en Cancérologie de Lyon
( 139829 )
- 28, rue Laennec - 69373 Lyon
- France
3
UCBL -
Université Claude Bernard Lyon 1
( 194495 )
- 43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex
- France
4
Hôpital Edouard Herriot [CHU - HCL]
( 300094 )
- 5 Place d'Arsonval
69003 Lyon
- France
|
Licence |
Paternité - Pas d'utilisation commerciale - Pas de modification
|
Langue du document |
Anglais
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Date de publication |
2023-03-17
|
Nom de la revue |
|
Volume |
30
|
Numéro |
6
|
Domaine(s) |
|
DOI | 10.1530/erc-22-0395 |
Loading...